Denmark — Novo Nordisk plans to invest DKK 15.9 billion (approximately EUR 2.1 billion) starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.

Denmark — The healthcare company Novo Nordisk is investing DKK 2.1 billion (€ 282 M) in a new 10,300 sqm facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity.

Denmark — Novo Nordisk is investing € 67 M (500 million Danish kroner) in a new 19,000 sqm warehouse in Hillerød, Denmark. The warehouse will handle all inbound raw materials for Novo Nordisk's production in Denmark and will have a capacity of around 17,000 pallets.